Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety and Effectiveness of a Balanced 3rd Generation HES Solution (Tetraspan®) After Cardiac Surgery

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2011 by Rambam Health Care Campus.
Recruitment status was:  Not yet recruiting
Information provided by:
Rambam Health Care Campus Identifier:
First received: August 9, 2011
Last updated: August 16, 2011
Last verified: August 2011
The purpose of this randomized controlled trial in patients undergoing cardiac surgery is to show that a 3rd generation HES (Hydroxyethyl Starch) solution - Tetraspan® is as good as in terms of safety and effectiveness as the commonly used albumin based solution for volume replacement after the surgery.

Condition Intervention Phase
Elective Cardiac Surgery
Drug: Balanced hydroxyethyl starch solution
Drug: Ringer- albumin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Safety and Effectiveness of a Balanced 3rd Generation HES Solution (Tetraspan®) Versus Albumin Solution for Volume Replacement in Patients After Cardiac Surgery

Resource links provided by NLM:

Further study details as provided by Rambam Health Care Campus:

Primary Outcome Measures:
  • Chest tube drainage volume [ Time Frame: Total volume at the time of removal of drains (48 hours after surgery on average) ]

Secondary Outcome Measures:
  • Volume of replacement fluids given after surgery at each group [ Time Frame: Summary of volume replacement at the time of discharge from ICU (48 hours after surgery on average) ]
  • In hospital - all cause mortality [ Time Frame: End of hospitalization (5 days postsurgery on average) ]
  • 30-days all cause mortality [ Time Frame: 30 days from surgery ]
  • Incidence of kidney injury as defined by RIFLE criteria [ Time Frame: Duration of hospitalization after surgery (expected average duration of 5 days) ]
  • Incidence of coagulopathy as defined by prolonged PT\PTT and abnormal thromboelastogram not due to clotting inhibitors during hospitalization. [ Time Frame: Duration of hospitalization after surgery (expected average duration of 5 days) ]
  • Volume of Transfused blood products during hospitalization postsurgery [ Time Frame: Duration of hospitalization after surgery (expected average duration of 5 days) ]

Estimated Enrollment: 300
Study Start Date: August 2011
Estimated Study Completion Date: August 2013
Estimated Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Ringer-albumin
Patients receiving the standard care of ringer-albumin as volume replacement after cardiac surgery
Drug: Ringer- albumin
Patients receiving lactated ringer-albumin solution for volume replacement after cardiac surgery
Other Names:
  • HARTMANN Solution
  • Human albumin 20%- Zenalb
Experimental: Tetraspan
patients receiving a 3rd generation HES solution (tetraspan) for volume replacement after cardiac surgery
Drug: Balanced hydroxyethyl starch solution
Patients receiving Tetraspan 6% ( a balanced 3rd generation Hydroxyethyl starch)for volume replacement after elective cardiac surgery as needed.
Other Name: Tetraspan


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent must be obtained from the subject or his/her legal guardian before any assessment is performed.
  • Male or Female subject, 18 years or older.
  • Any elective cardiac surgery

Exclusion Criteria:

  • Subjects with impaired liver function defined as an elevated level of ALT and AST over 100 U/L.
  • Hyperhydration states (e.g. pulmonary edema, congestive heart failure).
  • Renal failure with creatinine blood levels > 2.5 mg/dL or eGFR < 30 ml/min (calculated using the DMRD formula).
  • Oliguria (UO<0.5ml\kg\hr) or anuria (not related to hypovolemia) more than 12 hours.
  • Current Intracranial hemorrhage.
  • Current, hard to balance hyperkalemia.
  • Severe hypernatremia or severe hyperchloremia.
  • Known hypersensitivity to hydroxyethyl starch or to any of the excipients.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01418521

Contact: Liran Shani, MD 972-8542631

Rambam health care campus Not yet recruiting
Haifa, Israel
Contact: Liran Shani, MD   
Sponsors and Collaborators
Rambam Health Care Campus
Principal Investigator: Zvi Adler, MD Rambam Health Care Campus
  More Information

Responsible Party: Zvi Adler, Rambam Health Care Campus, cardiac surgery department Identifier: NCT01418521     History of Changes
Other Study ID Numbers: RMB-0058.CTIL
Study First Received: August 9, 2011
Last Updated: August 16, 2011

Keywords provided by Rambam Health Care Campus:
Cardiac surgery
Balanced 3rd generation Hydroxyethyl starch

Additional relevant MeSH terms:
Pharmaceutical Solutions
Hydroxyethyl Starch Derivatives
Plasma Substitutes
Blood Substitutes processed this record on May 24, 2017